Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

First-trimester screening for aneuploidy.

Karlla W Brigatti1, Fergal D Malone

  • 1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, Columbia Presbyterian Medical Center, 622 West 168th Street, PH16, New York, NY 10032, USA.

Obstetrics and Gynecology Clinics of North America
|April 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trial-ready external controls for gene therapy: The MATCH cohort in maple syrup urine disease.

Cell reports. Medicine·2026
Same author

Bi-allelic loss-of-function variants in JKAMP cause a neurodevelopmental syndrome associated with dysregulation of GPR37 trafficking.

American journal of human genetics·2026
Same author

Metformin therapy to facilitate weight loss in adults with classic maple syrup urine disease.

Molecular genetics and metabolism·2026
Same author

Urine Sorbitol and Xylitol for the Diagnosis of Sorbitol Dehydrogenase Deficiency-Related Neuropathy.

Neurology·2025
Same author

Characterization of a PNLIP variant identified in Amish pediatric patients with congenital pancreatic lipase deficiency.

Journal of lipid research·2025
Same author

Exonic Variation and Its Clinical Impact in 7221 Old Order Amish.

American journal of medical genetics. Part A·2025
Same journal

Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evaluation and Management of the Pediatric Gender-Diverse Patient.

Obstetrics and gynecology clinics of North America·2026
Same journal

Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

Obstetrics and gynecology clinics of North America·2026
Same journal

Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

Obstetrics and gynecology clinics of North America·2026
Same journal

Contraceptive Needs of the Transmasculine Patient.

Obstetrics and gynecology clinics of North America·2026
See all related articles

First-trimester prenatal screening for aneuploidy using new ultrasound and serum markers offers improved detection over second-trimester methods. This review covers current screening for Down syndrome and implementation challenges in the US.

Area of Science:

  • Maternal-fetal medicine
  • Prenatal diagnostics
  • Genetics

Background:

  • Current prenatal screening for fetal aneuploidy primarily relies on second-trimester methods.
  • These methods have limitations in detection rates and timing.

Purpose of the Study:

  • To review the current status of first-trimester screening for fetal aneuploidy, including Down syndrome.
  • To explore the challenges associated with implementing these advanced screening methods into routine prenatal care in the United States.

Main Methods:

  • Review of existing literature on first-trimester aneuploidy screening.
  • Analysis of novel ultrasound markers (e.g., nuchal translucency) and maternal serum markers (e.g., PAPP-A, free beta-hCG).
  • Discussion of logistical and clinical implementation issues for widespread adoption.

Related Experiment Videos

Main Results:

  • First-trimester screening demonstrates improved detection rates for aneuploidies compared to traditional second-trimester methods.
  • Novel marker combinations enhance the accuracy of prenatal screening.
  • Implementation requires addressing healthcare provider training, patient counseling, and laboratory infrastructure.

Conclusions:

  • First-trimester screening for aneuploidy is a viable and promising advancement in prenatal care.
  • Widespread adoption in the US necessitates overcoming specific implementation hurdles.
  • Early detection of fetal aneuploidies allows for timely management and informed decision-making.